Risk of ischaemic stroke associated with intravitreal bevacizumab -- a hospital-based case-crossover study.
Department of Ophthalmology, Taipei City Hospital, Heping Fuyoy Branch, Taipei, Taiwan.
Ming-Hung
MH
Hsieh
Chia-Chin
CC
Liao
Jen-Chieh
JC
Lin
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D002545:Brain Ischemia / Q000139:chemically induced* / Q000175:diagnosis; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab